Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Nantes – page 30

951 clinical trials in Nantes, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Nantes at a glance
951
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

951 trials in Nantes

Open in trial search

Neoplasm

Recruiting

Continued Cancer Treatment Study with Abiraterone, Ipatasertib, Tiragolumab, and Drug Combination for Patients from Previous Genentech/Roche Trials

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:F. Hoffmann-La Roche AG

Pneumonia

Recruiting

Study Comparing Amoxicillin and Amoxicillin/Clavulanic Acid for Treating Community-Acquired Pneumonia in Patients Aged 65 and Older

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Amoxicillin
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Study on Long-term Safety and Efficacy of Efgartigimod PH20 SC in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Rheumatoid arthritis

Recruiting

Study on Abatacept for Rheumatoid Arthritis in Patients Responding to Initial TNF Inhibitor Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept
  • Sponsor:Centre Hospitalier Universitaire De Montpellier

Acute myeloid leukaemia

Recruiting

Study Comparing CPX-351 and Chemotherapy for Patients with New Intermediate or High-Risk Acute Myeloid Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Centre Hospitalier Universitaire De Nice

Behavioural addiction

Recruiting

Study on Nalmefene and Placebo for Reducing Cravings in Patients with Gambling Disorder, Sexual Addiction, or Food Addiction

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Centre Hospitalier Universitaire De Nantes

PIK3CA related overgrowth spectrum

Recruiting

Study on the Effects and Safety of Alpelisib for Children and Adults with Megalencephaly-Capillary Malformation Polymicrogyria Syndrome

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Alpelisib
  • Sponsor:Centre Hospitalier Universitaire De Dijon

General anaesthesia

Recruiting

Study on the Effects of Dexmedetomidine and Midazolam on Children's Experience After General Anesthesia

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Midazolam
  • Sponsor:Centre Hospitalier Universitaire De Montpellier

Pre-eclampsia

Recruiting

Study on Aspirin for Preventing Preeclampsia in First-Time Pregnant Women Using Assisted Reproductive Technology

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Chronic kidney disease+1

Recruiting

Study on Blood Pressure Management with Amiloride Hydrochloride, Indapamide, and Furosemide for Patients with Uncontrolled Hypertension and Chronic Kidney Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Furosemide
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Acute lymphocytic leukaemia

Recruiting

Study on Methotrexate and Dexamethasone for Infants Under One Year with Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Asparaginase
  • Sponsor:Princess Maxima Center For Pediatric Oncology

Renal transplant

Recruiting

Study on Switching from Tacrolimus or Ciclosporin to Belatacept for Adolescents with Kidney Transplants

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Belatacept
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Nantes

What the registry says about research in the country

01 Oncology and Hematology

Advanced research focusing on multiple myeloma, leukemia, and various lymphomas. Studies are evaluating novel treatment combinations and therapeutic approaches for blood cancers.

  • Multiple Myeloma Treatments
  • Lymphoma Therapies
  • Leukemia Management

Innovative trials exploring combinations of targeted therapies and immunotherapies to improve patient outcomes.

02 Infectious Diseases

Comprehensive studies on preventive measures against viral infections, including trials for vaccines targeting CMV, yellow fever, and mpox.

  • Vaccine Development
  • Viral Prevention
  • Immunization Studies

Focus on developing and evaluating new vaccine formulations and delivery methods.

03 Autoimmune Conditions

Research investigating treatments for inflammatory bowel diseases and multiple sclerosis, including innovative approaches like fecal microbiota transplantation.

  • Crohn's Disease
  • Ulcerative Colitis
  • MS Treatment Strategies

Exploring novel therapeutic options and treatment de-escalation strategies.

04 Critical Care Medicine

Studies addressing postoperative care and management of severe conditions in intensive care settings, including burns and immune suppression.

  • Post-Surgery Care
  • Burn Treatment
  • ICU Interventions

Evaluating new approaches to improve patient comfort and outcomes in critical care.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.